Literature DB >> 468994

Radioimmunochemical quantitation of human adenosine deaminase.

P E Daddona, M A Frohman, W N Kelley.   

Abstract

Markedly reduced or absent adenosine deaminase activity in man is associated with an autosomal recesive form of severe conbined immunodeficiency disease. To further define the genetic nature of this enzyme defect, we have quantitated immunologically active adenosine deaminase (CRM) in the hemolysate of homozygous deficient patients and their heterozygous parents. A highly specific radioimmunoassay was developed capable of detecting 0.05% of normal erythrocyte adenosine deaminase. Hemolysates from nine heterozygotes (five families) showed a wide range in CRM (32--100% of normal) and variable absolute specific activities with several being at least 1 SD BELOW THE NORMAL MEAN. Hemolysates from four unrelated patients showed less than 0.09% adenosine deaminase activity with CRM ranging from less than 0.06 to 5.6% of the normal mean. In conclusion, heterozygote and homozygote hemolysates from five of the eight families analyzed revealed variable levels of CRM suggesting heterogeneous genetic alteration or expression of the silent or defective allele(s) of adenosine deaminase.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 468994      PMCID: PMC372184          DOI: 10.1172/JCI109526

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  14 in total

1.  Human adenosine deaminase. Purification and subunit structure.

Authors:  P E Daddona; W N Kelley
Journal:  J Biol Chem       Date:  1977-01-10       Impact factor: 5.157

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  Adenosine-deaminase deficiency and combined immunodeficiency syndrome.

Authors:  J Dissing; B Knudsen
Journal:  Lancet       Date:  1972-12-16       Impact factor: 79.321

4.  Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity.

Authors:  E R Giblett; J E Anderson; F Cohen; B Pollara; H J Meuwissen
Journal:  Lancet       Date:  1972-11-18       Impact factor: 79.321

5.  Molecular form of adenosine deaminase in severe combined immunodeficiency.

Authors:  M B Van der Weyden; R H Buckley; W N Kelley
Journal:  Biochem Biophys Res Commun       Date:  1974-04-08       Impact factor: 3.575

6.  Adenosine deaminase activity in normal tissues and tissues from a child with severe combined immunodeficiency and adenosine deaminase deficiency.

Authors:  R Hirschhorn; F Martiniuk; F S Rosen
Journal:  Clin Immunol Immunopathol       Date:  1978-03

7.  Use of protein A--containing Staphylococcus aureus as an immunoadsorbent in radioimmunoassays to separate antibody-bound from free antigen.

Authors:  M A Frohman; L A Frohman; M B Goldman; J N Goldman
Journal:  J Lab Clin Med       Date:  1979-04

8.  Severe combined immunodeficiency and adenosine deaminase deficiency.

Authors:  R Parkman; E W Gelfand; F S Rosen; A Sanderson; R Hirschhorn
Journal:  N Engl J Med       Date:  1975-04-03       Impact factor: 91.245

9.  Quantitative immunoassay of adenosine deaminase in combined immunodeficiency disease.

Authors:  D A Carson; R Goldblum; J E Seegmiller
Journal:  J Immunol       Date:  1977-01       Impact factor: 5.422

10.  Characterization of residual enzyme activity in fibroblasts from patients with adenosine deaminase deficiency and combined immunodeficiency: evidence for a mutant enzyme.

Authors:  R Hirschhorn; N Beratis; F S Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  1976-01       Impact factor: 11.205

View more
  7 in total

1.  Concentration of NADH-cytochrome b5 reductase in erythrocytes of normal and methemoglobinemic individuals measured with a quantitative radioimmunoblotting assay.

Authors:  N Borgese; G Pietrini; S Gaetani
Journal:  J Clin Invest       Date:  1987-11       Impact factor: 14.808

2.  Adenosine deaminase deficiency with normal immune function. An acidic enzyme mutation.

Authors:  P E Daddona; B S Mitchell; H J Meuwissen; B L Davidson; J M Wilson; C A Koller
Journal:  J Clin Invest       Date:  1983-08       Impact factor: 14.808

3.  Immunological and catalytic quantitation of splenic glucocerebrosidase from the three clinical forms of Gaucher disease.

Authors:  P G Pentchev; B Neumeyer; L Svennerholm; C G Groth; R O Brady
Journal:  Am J Hum Genet       Date:  1983-07       Impact factor: 11.025

4.  Biochemical and functional abnormalities in lymphocytes from an adenosine deaminase-deficient patient during enzyme replacement therapy.

Authors:  J J Hutton; D A Wiginton; M S Coleman; S A Fuller; S Limouze; B C Lampkin
Journal:  J Clin Invest       Date:  1981-08       Impact factor: 14.808

Review 5.  Analysis of normal and mutant forms of human adenosine deaminase - a review.

Authors:  P E Daddona; W N Kelley
Journal:  Mol Cell Biochem       Date:  1980-02-08       Impact factor: 3.396

6.  Basic defect in the expression of adenosine deaminase in ADA-SCID disease. II. Deficiency of ADA-CRM detected in heterozygote human-Chinese hamster cell hybrids.

Authors:  E Herbschleb-Voogt; J W Scholten; P Meera Khan
Journal:  Hum Genet       Date:  1983       Impact factor: 4.132

7.  A new approach to detection of heterozygotes for adenosine deaminase deficiency: a hypothetical method.

Authors:  N Sakura; T Usui; K Ito; K S Ha; T Ikeda; H Yabuuchi; N Iwanami; A Komiyama; T Akabane
Journal:  Eur J Pediatr       Date:  1981-10       Impact factor: 3.183

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.